Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
about
Concise review: Leukemia stem cells in personalized medicineAberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic targetUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesGAS6 expression identifies high-risk adult AML patients: potential implications for therapyA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupNew strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicThe NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabinePhase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive TherapyInhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Frontline therapy of AML: should the older patient be treated differently?Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Acute myeloid leukemia in the elderly: therapeutic options and choice.Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells.The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.The role of the proteasome in AML.An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.Expert insights into the contemporary management of older adults with acute myeloid leukemia.(Immuno)proteasomes as therapeutic target in acute leukemia.Nuclear FOXM1 drives chemoresistance in AML.Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.Proteasome inhibitors in cancer therapy.Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).FOXM1 contributes to treatment failure in acute myeloid leukemia
P2860
Q26995268-4863288D-1368-420D-90F5-8DFD813E73B5Q26995561-D96E7CBF-E205-4A5A-9EE0-79DF67D9D974Q28071384-4B19FC6B-B938-445C-AA5A-28007ED62A0BQ30248842-8D7AE1D2-BB0F-4906-90A4-D71056D2C8A4Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEFQ30313615-161735A2-866D-417A-BED0-092024E9E8FFQ33437992-07B86E2B-3D3F-4BDB-945B-6372380671D5Q33630851-8044800B-C50F-4059-A89B-F3D0D421AA41Q33653485-4B01CF7E-3C14-49FC-AF8B-54D0A140E7ADQ33705743-E0232306-8541-4BC1-97A9-A2A926E1708CQ33717707-235DE46E-86FF-4B7C-8D40-43AE616582DCQ34585047-435A5AAB-4E30-4966-9721-3887F704E466Q34715598-60D651A7-89A4-48C3-A3B6-78BD36BAC29FQ34788381-91F873D6-13AE-4CC0-A524-CD52116097D9Q34817365-DD02C92C-FFAF-438C-9084-BD812B26C92EQ34979606-DF8FA1F7-6193-49E6-9C9C-0711D1E9744FQ36848774-BAE7BF2B-7177-4799-A861-C4BCA3AB5766Q37109858-75F2CFFC-2FFB-47D0-874E-A5464D85B48FQ37338371-B9B8C071-DEB1-4178-8D48-2F8EEA400BEBQ37349410-0AE1367E-F410-4D73-A932-F0979C644C43Q37386171-8AFA7640-3111-42B7-8380-03802163F769Q37396013-F41A9D36-09DA-4990-8D10-BD18A807D630Q37643136-33E9477E-F554-4065-9060-A911CC567967Q37672544-32383CB0-D365-4130-807F-27BE9F2AC9D1Q38212586-0C5D3BC4-6E96-4688-9FE3-566DDBB0CF56Q38222563-C555FA73-A1D1-4D00-8911-12437F43D9C0Q38542828-E1433471-D5FA-4EA3-A17B-31743BF416C3Q38675781-BAC6D582-50B2-4EFE-B439-A7895E623ED2Q38875074-37BDA4C1-654D-464B-987C-8C7A60F916E2Q38892311-E906BE2C-5525-4B2A-90A0-F1CACD83964CQ39027087-D7CDADEC-CC05-4BA1-BB0B-4D6167C2A86FQ40261354-61AFEFBE-9DF5-455B-AB63-D3FFB622CEDAQ41856711-21856655-AA3C-4E3F-AEDC-CB2C78FD8547Q44898238-1B196304-589D-4061-8F27-55C076B72FFBQ47131929-31CCB2E5-EB06-4018-A3FE-E78CDD7AA77EQ51439944-B535CC55-B13A-459A-9AA2-E15B2CC6F63CQ51818965-10C4050F-8EF0-41E5-BC9D-13B85A4F3855Q53752929-F464412B-805A-4D7C-9A24-1062B557BC99Q54964566-EC9CE6DE-AFE3-4894-943A-3BA9F0F95FF5Q58792314-E651EDDF-6390-4577-A720-06CB4300B4E3
P2860
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@ast
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@en
type
label
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@ast
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@en
prefLabel
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@ast
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@en
P2093
P2860
P50
P356
P1476
Bortezomib added to daunorubic ...... CALGB (Alliance) study 10502.
@en
P2093
Barry Moser
Bayard L Powell
Daniel J DeAngelo
Eunice S Wang
Eyal C Attar
Gerard Lozanski
Jeffrey L Johnson
Jonathan E Kolitz
Peter Voorhees
Philip C Amrein
P2860
P304
P356
10.1200/JCO.2012.45.2177
P407
P577
2012-11-05T00:00:00Z